Regulatory Reform in China: Implications for Global Biopharmaceutical Companies

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China. To compete in this resource-intensive manufacturing process that requires large volume capacity and a technically trained labor force, it is logical pharmaceutical companies will turn to contract manufacturing in China to meet strategic sourcing requirements.

Download the

.